Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2013

View Archived Issues

Identification of a plasma biomarker to assess resistant GVHD

Novel M4 receptor modulators presented by The Vanderbilt University

Amicus Therapeutics collaborates with Biogen Idec for Parkinson's disease drugs

Eliglustat noninferior to imiglucerase in phase III ENCORE study

Phase IIb AllerT birch pollen allergy vaccine study meets primary endpoint

SMT-19969 shows selective activity against C. difficile infection

Antisense oligonucleotides synergistically inhibit prostate cancer cell growth in vitro and in vivo

Amgen presents novel GPR119 agonists at ACS meeting

Dainippon Sumitomo Pharma reports discovery of glucagon receptor antagonists

Kakeromycin may represent a new class of antifungals

Wayne State University discloses new gene constructs for cancer

First patient treated in Neuralstem's phase II trial in ALS

Roche acquires license to Inovio's DNA-based prostate cancer and hepatitis B vaccine candidates

ChemoCentryx reports interim data for CCX-140 in patients with diabetic nephropathy

Actelion to initiate phase III program of cadazolid for CDAD

FCGR3A gene and its association with sarcoidosis

RedHill Biopharma's RHB-104 shows potential for treatment of lupus

ALS Therapy Development Institute and Anida Pharma form partnership

Theraclone Sciences begins phase IIa trial of TCN-202 for prevention of CMV

FDA grants breakthrough therapy designation to entinostat in advanced breast cancer

Janssen Biotech initiates phase II study of daratumumab in multiple myeloma

Dosing begins in phase II trial of Conatus' emricasan in severe alcoholic hepatitis

Verastem commences phase II trial of defactinib in mesothelioma

Exelixis begins CELESTIAL phase III trial of cabozantinib

Italian group discloses novel GSK-3 beta inhibitors

FDA committee recommends accelerated approval of new indication for Genentech's Perjeta

FDA grants fast track designation to Synta's ganetespib in non-small cell lung adenocarcinoma

Sanofi withdraws lixisenatide NDA in the U.S.